TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04922723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered by IV infusion to subjects in combination with current therapeutic strategies of surgical resection followed by a course of Temozolomide and radiation therapy.
Study: NCT04851847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Description: Use of resorbable collagen membrane to treat periodontal intrabony defects.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Tissue Regeneration (GTR)
Description: Use of resorbable collagen membrane to treat periodontal intrabony defects.
Study: NCT04893473

Intervention type: DEVICE
Intervention: IscAlert
Description: 3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and carbon dioxide is measured continuously.

Intervention type: DEVICE
Intervention: IscAlert
Description: 3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and carbon dioxide is measured continuously.
Study: NCT05276492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Oral Tablet
Description: Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Oral Tablet
Description: Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Oral Tablet
Description: Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
Study: NCT04843189

Intervention type: PROCEDURE
Intervention: Da Vinci Robotic Surgery
Description: Da Vinci Robotic Surgery

Intervention type: PROCEDURE
Intervention: Da Vinci Robotic Surgery
Description: Da Vinci Robotic Surgery
Study: NCT06163768

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insulin resistance
Description: Steps to conduct testing and treatment according to the approved regimen at Ho Chi Minh City University of Medicine and Pharmacy Hospital. The researcher did not intervene in the treatment process.
Study: NCT05631873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assistance with implementing Epic Smartlist
Description: A research assistant helps GI providers add a new SmartList in to patient letters in Epic EHR that auto populates the colonoscopy recommendation time interval in patient records
Study: NCT05351866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBT-based mobile intervention for depression
Description: SparkRx is a 5-week program divided into levels intended to be completed weekly. SparkRx is a behavioral activation program. Participants are instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and participant symptom check (PSC) in the mobile app. Tasks in the mobile app progress in a linear fashion (i.e., each task must be completed to progress to the next task).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile control with education about depression
Description: The control mobile application will consist of 5 weeks of educational content about depression. Participants will be instructed to complete a weekly Patient Health Questionnaire (PHQ)-8 assessment and PSC in the mobile app.
Study: NCT05276492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Oral Tablet
Description: Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.
Study: NCT06447402

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 5 mL of normal saline will be nebulised in the control arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate
Description: 2 mL of the above reconstituted amphotericin B solution will be obtained in a sterile syringe and transferred into the drug chamber of a nebulizer. Three mL of distilled water will be added to 2 mL of the reconstituted amphotericin B (5 mL liquid in the chamber ensures complete and easy nebulization of all the contents)
Study: NCT06015087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fasting diet
Description: A total of 50 patients with breast cancer will be randomly devided in intervention and control group. Intervention group will follow a 60 hours fasting diet (36h prior and 24h after chemotherapy infusion), low in calories, mainly plant based, and the Mediterranean Diet in the meantime between chemotherapy cycles. Control group will receive only standard of care. Nutritional counseling and dietary records will be performed by registered dietitian. Adherence to the Mediterranean Diet will be estimated with MedDietScore. Grade of toxicity will be estimated by using the National Cancer Institute Common Terminology Criteria for Adverse Events. All participants will be encourange to continue usual physical activity.
Study: NCT06272110

Intervention type: OTHER
Intervention: System level Language Access (LA) intervention
Description: Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.

Intervention type: OTHER
Intervention: System level Language Access (LA) intervention
Description: Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.

Intervention type: OTHER
Intervention: System level Language Access (LA) intervention
Description: Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.

Intervention type: OTHER
Intervention: System level Language Access (LA) intervention
Description: Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.

Intervention type: OTHER
Intervention: System level Language Access (LA) intervention
Description: Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.

Intervention type: OTHER
Intervention: System level Language Access (LA) intervention
Description: Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.
Study: NCT05276492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone tablet
Description: Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Dairy/Log
Description: A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Dairy/Log
Description: A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Dairy/Log
Description: A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Dairy/Log
Description: A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-fat meal
Description: A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-fat meal
Description: A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-fat meal
Description: A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-fat meal
Description: A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff.
Study: NCT05527431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal cannula
Description: high flow nasal cannula
Study: NCT05486611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: W-GenZD Mobile Application
Description: W-GenZD is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Digital Education Application (W-EdZD)
Description: Digital Education will be available to the participant via the 'Quest GenZ' smartphone application but will be devoid of active elements included in WB002. We will source this material from kidshealth.org, which is supported by Nemours Children's Health. We have received permission to use their content.~The materials are written at an 8th grade reading level and will include general health (e.g., food plate guide, caffeine, online safety, study skills) articles. A new article will be provided to the participant at a rate of once per week across the 4 weeks (4 articles total) and they will receive a weekly notification when a new article is available. Each article will be available for one week from release date.
Study: NCT05527431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive ventilation
Description: noninvasive ventilation
Study: NCT06361628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent intervention on vaccination awareness
Description: Educational sessions to create awareness on HPV and MMR (were addressed) vaccination that is culturally sensitive health information and provided in an easily understandable manner by trained health promoters (and healthcare professionals) to underserved communities. Support for navigation and access to vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent intervention on vaccination awareness
Description: Educational sessions to create awareness on HPV and MMR (were addressed) vaccination that is culturally sensitive health information and provided in an easily understandable manner by trained health promoters (and healthcare professionals) to underserved communities. Support for navigation and access to vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent intervention on vaccination awareness
Description: Educational sessions to create awareness on HPV and MMR (were addressed) vaccination that is culturally sensitive health information and provided in an easily understandable manner by trained health promoters (and healthcare professionals) to underserved communities. Support for navigation and access to vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent intervention on vaccination awareness
Description: Educational sessions to create awareness on HPV and MMR (were addressed) vaccination that is culturally sensitive health information and provided in an easily understandable manner by trained health promoters (and healthcare professionals) to underserved communities. Support for navigation and access to vaccines.
Study: NCT04262895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-0102
Description: TTI-0102 is a cysteamine precursor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-0102
Description: TTI-0102 is a cysteamine precursor.
Study: NCT05641922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioTraceIO 360
Description: Use of the device for planning, monitoring and assessment of liver tissue ablations
Study: NCT04262895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05038007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: As prior described

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: As prior described
Study: NCT05278663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: E6742 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6742
Description: E6742 tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6742-matching placebo tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6742-matching placebo tablet.
Study: NCT06566157

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: WellBiome® prebiotic complex: Inulin 67%, XOS 27%, Magnesium Chloride (MgCl2) 9.8 %

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (Corn)
Description: Placebo
Study: NCT05744466

Intervention type: DRUG
Intervention: Deucravacitinib
Description: As prescribed by treating clinician

Intervention type: DRUG
Intervention: Apremilast
Description: As prescribed by treating clinician
Study: NCT05325333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-based word learning
Description: Learning sessions: Novel nouns and their meanings are practiced on Day 1. In both conditions, retrieval trials will initially be immediate. In the expanding condition, the next two retrieval trials will each occur after 1 intervening word and then after 3 intervening words for the remainder of the session. In the standard condition, all remaining retrieval trials will occur after 3 intervening words. This practice schedule is repeated the next day (Day 2).~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word and its meaning twice. One week after Day 1, this recall test is completed again. At this time, the child will complete a recognition test: viewing sets of 4 pictures, the child will hear each novel noun and point to its referent in the array.
Study: NCT05942599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)
Description: Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg. BECAR33 Total duration of treatment: 28 days follow up: 12 months
Study: NCT04916808

Intervention type: DIAGNOSTIC_TEST
Intervention: DCISionRT Test
Description: The Prelude DCISionRT Test was developed by Prelude Corporation and is performed at its CLIA laboratory facility. The biomarkers used to evaluate the biologic signature of DCIS tissue are based on over a decade of research including the University of California, San Francisco, Yale University as well as Prelude Corporation. The test is prognostic for 10-year recurrence risk and predicts RT treatment benefit for invasive breast cancer. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing and is accredited by the College of American Pathologists (CAP).
Study: NCT04971720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet
Description: The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet
Description: The subject will be randomized, in a double-blind manner to sacubitril/valsartan 49/51 mg once in the morning or once in the evening for a period of 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg Oral Tablet
Description: The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg Oral Tablet
Description: The subject will be randomized, in a double-blind manner to valsartan 80 mg once in the morning or once in the evening for a period of 28 days.
Study: NCT04731272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75Mg/0.5Ml Inj Pen
Description: Randomized, open-label, cross-over study of 6 weeks exposure to dulaglutide 0.75 mg subcutaneous weekly or observation.
Study: NCT04984668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001+KN046
Description: GT90001 7.0mg/Kg， KN046 5mg/Kg
Study: NCT04148742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
Study: NCT05463016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Group 1: Color Correcting Lenses
Description: Color Correcting Lenses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group 1: Placebo Lenses
Description: Placebo Lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Group 1 Crosses over to become Experimental Group 2: Color Correcting Lenses
Description: Color Correcting Lenses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Experimental Group 1 Crosses over to become Placebo Group 2: Placebo Lenses
Description: Placebo Lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Color Correcting Lenses in Subjects with Normal Color Vision
Description: Color Correcting Lenses
Study: NCT04984668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001+KN046
Description: GT90001 7.0mg/Kg ， KN046 3mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001/KN046
Description: GT90001 4.5mg/Kg / KN046 5mg/Kg
Study: NCT05594628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: Neuromuscular training is designed as 8 weeks and 2 times a week, and approximately 20 minutes per session for Neuromuscular training+usual basketball training group. Other group is only going to keep attending usual basketball training.~Neuromuscular training consisted 3 exercises:~First exercise is passing the ball to side to side on bosu with standing on one leg. 60-90 seconds on time, 30-60 seconds off time. 2 sets for both passing sides and bilaterally.~Second exercise is standing on bosu unilaterally and while standing stabilized, switching basketball hand to hand as dribbling on the floor. Exercise will be on for 60-90 seconds and off for 30-60 seconds, 2 sets for each side Third exercise is jumping with one stance/leg, and landing with double stance while a therabant is attached to the belly and pulling with a minimum/medium force from one side. Changing legs after one jump, 6 times for both side is equal to 1 set of the exercise. It will be done 2 sets for both sides.
Study: NCT04984668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001+KN046
Description: GT90001 4.5mg/Kg， KN046 3mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001+KN046
Description: GT90001 3mg/Kg ， KN046 3mg/Kg
Study: NCT05921799

Intervention type: PROCEDURE
Intervention: Blood specimen collection
Description: Routinely collect citrate blood and native blood from patients as required by their condition.
Study: NCT04563962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management-ART
Description: Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated adherence to tenofovir-based ART or PrEP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management-Methamphetamine
Description: Participants in this arm will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.